Insider Buying: Fortress Biotech (NASDAQ:FBIO) CEO Acquires 17,456 Shares of Company Stock

Fortress Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Fortress Biotech CEO Lindsay Rosenwald bought 17,456 shares at an average price of $1.86, spending about $32,468; the purchase increased his direct holdings to 4,723,564 shares.
  • FBIO shares fell 5.7% to $1.78 during Thursday trading, near the stock’s 52-week low of $1.64.
  • The company reported a quarterly loss of $0.23 per share, beating the $0.27 loss analysts expected, while revenue of $19.16 million fell short of the $21.57 million estimate.
  • Five stocks we like better than Fortress Biotech.

Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) CEO Lindsay Md Rosenwald bought 17,456 shares of the stock in a transaction on Thursday, November 19th. The stock was purchased at an average cost of $1.86 per share, with a total value of $32,468.16. Following the purchase, the chief executive officer directly owned 4,723,564 shares of the company's stock, valued at approximately $8,785,829.04. This represents a 0.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Fortress Biotech Trading Down 5.7%

FBIO traded down $0.11 during mid-day trading on Thursday, hitting $1.78. The stock had a trading volume of 194,841 shares, compared to its average volume of 586,980. The stock's fifty day simple moving average is $2.08 and its 200-day simple moving average is $2.70. The firm has a market capitalization of $60.16 million, a price-to-earnings ratio of 0.78 and a beta of 1.27. Fortress Biotech, Inc. has a 1-year low of $1.64 and a 1-year high of $4.53. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.93 and a quick ratio of 3.83.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. The company had revenue of $19.16 million during the quarter, compared to analyst estimates of $21.57 million.

Key Fortress Biotech News

These are some of the FBIO news items that stood out recently:

  • Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
  • Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article

Analysts Set New Price Targets

FBIO has been the topic of several recent analyst reports. Wall Street Zen lowered Fortress Biotech from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 15th. Weiss Ratings downgraded Fortress Biotech from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, October 23rd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $17.00.

View Our Latest Report on FBIO

Institutional Investors Weigh In On Fortress Biotech

A number of institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC bought a new position in Fortress Biotech during the second quarter worth about $47,000. Renaissance Technologies LLC raised its stake in Fortress Biotech by 22.8% in the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company's stock valued at $278,000 after buying an additional 18,490 shares during the period. Finally, Marshall Wace LLP bought a new stake in Fortress Biotech in the third quarter valued at approximately $462,000. 96.51% of the stock is owned by institutional investors.

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company's activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fortress Biotech Right Now?

Before you consider Fortress Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.

While Fortress Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines